Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleonopathies

Edward Rockenstein
University of California - San Diego

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat
Part of the Immunology and Infectious Disease Commons, and the Translational Medical Research Commons


Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
COMBINED ACTIVE HUMORAL AND CELLULAR IMMUNIZATION APPROACHES FOR THE TREATMENT OF SYNucleinopathies

Edward Rockenstein¹, Gary Ostroff², Fusun Dikengil³, Florentina Rus², Michael Mante¹, Jazmin Florio¹, Anthony Adame¹, Ivy Trinh¹, Cassia Overk¹, Eliezer Masliah¹ and Robert Rissman¹
¹Department of Neurosciences, University of California, San Diego, La Jolla, CA; ²Program in Molecular Medicine, and ³Internal Medicine, University of Massachusetts Medical School

Objectives: Parkinson’s Disease (PD), Dementia with Lewy bodies (DLB), and Multiple System Atrophy (MSA) are neurodegenerative disorders of the aging population characterized by the progressive accumulation of alpha-synuclein. Jointly these disorders have been denominated synucleinopathies and currently no disease modifying treatments are available. Previous in vivo studies in transgenic (tg) mice have shown that active and passive immunization targeting alpha-synuclein ameliorates to some extent deficits and synuclein accumulation, however it’s unknown if combining humoral and cellular immunization might synergize and also reduce inflammation and improve microglial cell mediated synuclein clearance.

Methods: PDGF- alpha-synuclein tg mice and control non-tg mice were immunized with: 1) Glucan Particle (GP) adjuvant alone, 2) GP human (hu)- alpha-synuclein (active immunization), 3) GP plus rapamycin and 4) GP plus rapamycin and hu-alpha-synuclein (combined active and humoral) and analyzed by neuropathological and biochemical markers.

Results: Compared to tg mice treated with adjuvant alone, mice immunized with GP hu-alpha-synuclein displayed a 30% reduction in alpha-synuclein accumulation. Combined immunotherapy with GP plus rapamycin and hu-alpha-synuclein resulted in 50% reduction in alpha-synuclein accumulation which was accompanied by reduced neuro-inflammation (Iba-1, GFAP, IL6, TNFalpha), phospho and insoluble alpha-synuclein, microglia and astroglia cell numbers, and retention of CD25, FoxP3 and CD4 positive cells. Levels of TGFb1 were also increased. Serological studies showed that active immunization resulted in higher levels of total IgG, IgG1 and IgG2 titers, levels were slightly higher in the combined group.

Conclusions: In vivo studies targeting alpha-synuclein support the hypothesis that cellular immunization might enhance the effects of active immunotherapy for the treatment of synucleinopathies.

Contact:
Gary Ostroff, PhD
Research Professor
University of Massachusetts Medical School
Program in Molecular Medicine
gary.ostroff@umassmed.edu